A group of adults with type 1 diabetes who have not had insulin on average for 10 years and maintain near normal blood glucose thanks to beer transplantation, shows a new study.
Islet transplantation is where isolated islands – groups of pancreatic insulin-producing beta cells – are transplanted from a donor.
Researchers from the University of Miami's Diabetes Research Institute used continuous glucose monitoring to track transplant performance in five people with type 1 diabetes.
The results showed trends in glucose level control that were near normal as well as close to perfect time-in-range metrics.
Participants were given liver transplants (intrahepatic beer transplantation) from 2002 and 201
The researchers conducted a seven-day assessment with the participants wearing continuous glucose monitors for their glucose levels during the follow-up. Glucose levels were compared to that in adults with non-transplanted type 1 diabetes, but used the latest diabetes technology (a hybrid closed loop system) to help control their diabetes as well as possible.
The results of the comparison showed that each of the participants who had a transplant showed an improvement in the glucose content over time, as well as minor variations in glucose levels and lower exposure to low glucose (hypoglycaemia) levels.
Participants were chosen as those who had achieved excellent success after transplantation. Although these participants have achieved unusual results, it is not a guaranteed result of glacial grafts to stay free of insulin injections for many years. Many people undergoing the transplant should start taking some exogenous insulin (insulin not produced by the body itself) again after months or years depending on personal circumstances.
One of the leading researchers on the study, dr. David Baidal said: "Through continuous glucose monitoring, we now have the ability to accurately evaluate the patients' glucose profiles and their variability. The CGM data from our island transplant patients clearly shows that beer transplantation can result in glucose levels that are close to those in humans not has type 1 diabetes, even 10 years or more after undergoing the replacement procedure. "
Dr Camillo Ricordi, a Joy Goodman surgeon of surgery and the director of the Diabetes Research Institute, has been named the world's top beer transplant scientist. In his commentary on the study, he said: "This report confirms the superiority of transplantation of insulin-producing cells compared to insulin therapy, with results of glucose control that were even better than the targets of CGM in hybrid closed loop systems.
" Hopefully, This will help bring beer transplantation closer to FDA approval so that treatment can be made available to US patients, as has been the case in many other countries for many years. The results of the study were shared by the American Diabetes Association's 79th Scientific Sessions, which took place in San Francisco between June 7 and June 11. They will also be presented at the 17th World Congress of the International Pancreas and Islet Transplant Association, which takes place in France between July 2 and 5.